Table 2.
| Sites | HR transitional cell+ | HR squamous cell+ | HR papillary+ | HR other histologies+ |
|---|---|---|---|---|
| Renal pelvis | 1* | 4.30 (95% CI 3.40–5.44) | 0.81 (95% CI 0.47–1.39) | 1.28 (95% CI 1.04–1.58) |
| Ureter | 1* | 3.05 (95% CI 2.11–4.42) | 0.63 (95% CI 0.24–1.69) | 0.99 (95% CI 0.74–1.32) |
| Both sites | 1* | 3.68 (95% CI 3.02–4.50) | 0.77 (95% CI 0.48–1.25) | 1.10 (95% CI 0.93–1.30) |
| Cancer specific survival all stages | ||||
| Six months | 94.0% (95% CI 59.8%–73.9%) | 67.4% (95% CI 59.8%–73.9%) | 97.2% (95% CI 91.8%–99.1%) | 85.6% (95% CI 82.3%–88.3%) |
| One year | 89.7% (95% CI 89.2%–90.3%) | 54.3% (95% CI 46.4%–61.6%) | 93.5% (95% CI 86.9%–96.9%) | 80.0% (95% CI 76.3%–83.3%) |
| Two years | 84.5% (95% CI 83.8%–85.2%) | 40.6% (95% CI 32.7%–38.3%) | 90.4% (95% CI 82.9%–94.7%) | 74.5% (95% CI 70.3%–78.1%) |
| Five years | 79.1% (95% CI 78.2%–79.9%) | 32.5% (95% CI 24.6%–40.6%) | 84.1% (95% CI 74.8%–90.2%) | 68.2% (95% CI 63.5%–72.4%) |
| Cancer specific survival stage IV only | ||||
| Six months | 67.4% (95% CI 64.4%–70.2%) | 40.1% (95% CI 25.8%–54.0%) | NA | 58.3% (95% CI 47.9%–67.4%) |
| One year | 51.9% (95% CI 48.6%–55.1%) | 30.3% (95% CI 16.7%–45.0%) | NA | 45.6% (95% CI 35.0%–55.6%) |
| Two years | 36.9% (95% CI 33.4%–40.4%) | 26.5% (95% CI 13.4%–41.5%) | NA | 31.8% (95% CI 20.9%–43.3%) |
| Five years | 25.9% (95% CI 22.2%–29.7%) | 18.9% (95% CI 7.7%–34.0%) | NA | 20.0% (95% CI 8.8%–34.5%) |
Notes: Reference group;
HR for cancer specific mortality, adjusted for race, prior surgery and radiotherapy, decade of diagnosis, age at diagnosis, gender and stage. The table above describes the survival of patients with UUT malignancies across different histologies. The upper part demonstrates the outcome of the Cox Proportional Hazard model, adjusted for race, prior surgery and radiotherapy, decade of diagnosis, age at diagnosis, gender and stage. Patients with transitional cell histology were considered the reference group. The second part shows the cancer specifc survival for all stages and for patients with stage IV only, respectively. The cancer specific survival for patients with stage IV disease and papillary histology could, secondary to a paucity of cases not be calculated.